Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P130022/S067

Senza HFX iQ System

Nevro Corporation · Decision date Aug 15, 2025

FDA DECISIONP130022/S067

What did the FDA approve?

FDA records P130022/S067 as a supplement to PMA P130022, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated Aug 15, 2025.

FDA approval order statement

Approval for changes to the printed circuit board assembly (PCBA) board used in IPG3000, including replacing the microcontroller from rev 2 to rev 3, replacing the fuel gauge with a battery voltage measurement circuit, changing the material of the printed circuit board (PCB), moving the PCBA battery fuse from the negative terminal to the positive terminal, other minor modifications to PCB layout (reorganizing components and modification of solder pad size), as well as an alternate PCBA supplier for IPG3000.
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track
Clinical specialty
Neurology
Decision date
Aug 15, 2025
FDA change category
Change Design/Components/Specifications/Material

FDA source record

Regulatory record facts

Identifier
P130022/S067
Regulatory pathway
PMA supplement
Product code
LGW
Decision code
APPR
Decision date
Aug 15, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Stimulator, spinal-cord, totally implanted for pain relief.

Product code
LGW
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P130022/S067 received

    Application receipt date recorded by FDA.

  2. P130022/S067 · FDA decision

    Normal 180 Day Track

Timeline entries are records held by MedtechLedger for P130022. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P130022

Product / regulatory recordCompanyPathwayDecision dateSource
HFX Dynamis SystemP130022/S069
Nevro CorporationPMA supplementAug 18, 2026FDA

Explore the linked device profile

Other records with product code LGW

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Nevro Corporation

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
1800 Bridge Pkwy., Redwood City, CA, 94065

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records